You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Researchers found that TP53 mutations correlated with improved disease-free survival and overall survival in pancreatic cancer patients treated with gemcitabine following surgical resection.
Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.
After a study showed that patients who received guidance from Perthera's tumor board lived longer than those who didn't, the company wants to make its technology more accessible.
Mutated KRAS protein has been notoriously difficult to target with drugs, but MD Anderson researchers are trying to get at KRAS mRNA using exosomes.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
A roundup of some of the precision oncology-focused research presented at the Gastrointestinal Cancer Symposium in San Francisco, Jan. 23 to 25.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.
Increasing understanding of complex tumor biology is reshaping clinical trials in the age of precision medicine, though some view these changes with concern.
The drug is approved as a maintenance treatment for platinum-responsive metastatic pancreatic cancer patients with germline BRCA1/2 mutations.
A Phase I/II clinical trial for OBI-999, a new antibody-drug conjugate, is enrolling patients.